About Idera
• Letter to Stockholders
• Management Team
• Board of Directors
• Advisory Boards
• Corporate Governance
• Careers

Board of Directors

James B. Wyngaarden, M.D. ׀ Chairman of the Board of Directors
Youssef El Zein ׀ Vice Chairman of the Board of Directors
Sudhir Agrawal, D. Phil. ׀ Director
Robert W. Karr, M.D. ׀ Director
C. Keith Hartley ׀ Director
Hans Mueller, Ph.D. ׀ Director
William S. Reardon, C.P.A. ׀ Director
Alison Taunton-Rigby, Ph.D., OBE ׀ Director
Paul C. Zamecnik, M.D. ׀ Director Emeritus

Alison Taunton-Rigby, Ph.D., OBE ׀ Director
Dr. Taunton-Rigby was appointed a member of the Company's Board in September 2004.  Dr. Alison Taunton-Rigby has been Chief Executive Officer and Director of RiboNovix, Inc., a privately held development stage biotechnology company she co-founded, since February 2003.  Prior to founding RiboNovix, Dr. Taunton-Rigby was Chief Executive Officer of CMT, Inc., a healthcare technology company, from 2001 to 2003.  Previously, Dr. Taunton-Rigby was President and Chief Executive Officer of Aquila Biopharmaceuticals, Inc., a life sciences company, President and Chief Executive Officer of Cambridge Biotech Corporation, a life sciences company, and President and Chief Executive Officer of Mitotix, Inc., a biopharmaceutical company, Senior Vice President, Biotherapeutics at Genzyme Corporation, and held senior management positions at Biogen, Inc. (now Biogen Idec), Vivotech Inc., Collaborative Research, Inc. and Arthur D. Little.  Dr. Taunton-Rigby is also a director of Healthways, Inc., Abt Associates, and RiverSource Funds.